Warning labels on three anemia drugs used by one million Americans undergoing chemotherapy or who have kidney failure have been strengthened to alert users about increased risk of heart attack, stroke, a worsening of their condition, and even death, said the manufacturers, Amgen and Johnson & Johnson earlier this week.
The decision, which has been made in consultation with the US Food and Drug Administration, affects Amgen's Epogen and Aranesp, and Johnson & Johnson's Procrit. These drugs belong to a class known as erythropoiesis-stimulating agents or ESAs.
Related Posts
Subscribe to:
Post Comments
(
Atom
)
0 comments :
Post a Comment
Click to see the code!
To insert emoticon you must added at least one space before the code.